Pediatric Leukemia



A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.


Condition:   Lymphocytic Leukemia
Interventions:   Drug: NeoVax;   Drug: Cyclophosphamide
Sponsors:   Dana-Farber Cancer Institute;   Oncovir, Inc.;   Neon Therapeutics, Inc.
Not yet recruiting


Alternative Splicing and Leukemia Initiating Cells


Condition:   Acute Myeloid Leukemia
Intervention:   Other: Assessment of splicing variants
Sponsor:   Hospices Civils de Lyon
Recruiting


Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy


Condition:   Acute Promyelocytic Leukemia
Intervention:   Other: QoL questionnaires
Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting


Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia


Condition:   Leukemia
Intervention:   Biological: CD19-targeted CAR-T cells
Sponsors:   Sinobioway Cell Therapy Co., Ltd.;   The Second Hospital of Anhui Medical University
Recruiting


Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia


Condition:   Acute Promyelocytic Leukemia
Interventions:   Drug: Arsenic trioxide;   Drug: Idarubicin;   Drug: Cytarabine;   Drug: Tretinoin;   Drug: Mitoxantrone;   Drug: Mercaptopurine;   Drug: Methotrexate
Sponsors:   Technische Universität Dresden;   Gruppo Italiano Malattie EMatologiche dell'Adulto;   Groupe Francophone des Myelodysplasies;   Haemato Oncology Foundation for Adults in the Netherlands;   Programa para el Tratamiento de Hemopatías Malignas;   German Federal Ministry of Education and Research;   Teva Pharmaceuticals Europe
Recruiting


Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children


Condition:   Leukemia
Interventions:   Drug: Bortezomib;   Drug: Pravastatin
Sponsors:   Reuven Schore;   Millennium Pharmaceuticals, Inc.;   Hyundai Hope On Wheels
Recruiting


Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia


Condition:   Leukemia
Intervention:   Drug: BAY1143572
Sponsor:   Bayer
Completed


A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia


Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
Sponsors:   Dana-Farber Cancer Institute;   Pharmacyclics LLC.
Recruiting


Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin


Condition:   Leukemia
Interventions:   Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Recruiting


Biomarkers in Blood and Bone Marrow Samples From Patients With Acute Lymphoblastic Leukemia


Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Active, not recruiting


Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)


Condition:   Leukemia
Intervention:   Drug: Ara-c
Sponsor:   Chinese Academy of Medical Sciences
Recruiting


Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Active, not recruiting


Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia


Condition:   Leukemia
Interventions:   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
Completed


Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias


Condition:   Leukemia
Interventions:   Drug: Etoposide, Mitoxantrone, Clofarabine;   Drug: Clofarabine, Etoposide, Mitoxantrone
Sponsor:   Milton S. Hershey Medical Center
Completed


JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia


Condition:   Leukemia
Intervention:   Drug: JVRS-100
Sponsor:   Milton S. Hershey Medical Center
Active, not recruiting


A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib


Condition:   Leukemia
Intervention:   Drug: Dasatinib
Sponsor:   Bristol-Myers Squibb
Active, not recruiting


Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: Alemtuzumab;   Biological: Rituximab;   Biological: Sargramostim
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed


S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia


Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Completed


Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: fludarabine phosphate
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Terminated


Phase III Trial in Acute Promyelocytic Leukemia Patients


Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
Sponsors:   Gruppo Italiano Malattie EMatologiche dell'Adulto;   Study Alliance Leukemia (SAL) Group
Active, not recruiting


Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia


Condition:   Leukemia
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Innovative Therapies For Children with Cancer Consortium
Active, not recruiting


Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: rituximab;   Drug: lenalidomide
Sponsors:   Roswell Park Cancer Institute;   Celgene
Completed


Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia


Condition:   Leukemia
Intervention:   Drug: gemcitabine hydrochloride
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed


Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia


Condition:   Leukemia
Intervention:   Biological: denileukin diftitox
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
Completed


Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia


Condition:   Leukemia
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: fludarabine phosphate
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Completed

Refine Your Search Advanced Search